Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome

Clinical Biochemistry

Volumn 45, Issue 7-8, 2012, Pages 535-540

  Ristiniemi, Noora ^a   Lund, Juha ^b   Tertti, Risto ^b   Christensson, Anders ^c   Ilva, Tuomo ^d   Porela, Pekka ^b   Pulkki, Kari ^e,f   Pettersson, Kim ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c LUND UNIVERSITY   (Sweden)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f OK Kuopio   (Finland)

Author keywords

Acute coronary syndrome; Cystatin C; Kidney; Myocardial infarction; Renal insufficiency; Risk

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; CYSTATIN C;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; DEATH; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART INFARCTION; HUMAN; IMMUNOASSAY; KIDNEY FAILURE; KIDNEY FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PREDICTION; PRIORITY JOURNAL; RISK;

ACUTE CORONARY SYNDROME; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CREATININE; CYSTATIN C; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE;

EID: 84860210769     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.02.012     Document Type: Article

References (35)

1. Perkins B.A., Nelson R.G., Ostrander B.E.P., Blouch K.L., Krolewski A.S., Myers B.D., et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005, 16:1404-1412.
2. Pucci L., Triscornia S., Lucchesi D., Fotino C., Pellegrini G., Pardini E., et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 2007, 53:480-488.
3. Knight E.L., Verhave J.C., Spiegelman D., Hillege H.L., De Zeeuw D., Curhan G.C., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004, 65:1416-1421.
4. Pöge U., Gerhardt T., Bökenkamp A., Stoffel-Wagner B., Klehr H.-U., Sauerbruch T., et al. Time course of low molecular weight proteins in the early kidney transplantation period-influence of corticosteroids. Nephrol Dial Transplant 2004, 19:2858-2863.
5. Fliser D., Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001, 37:79-83.
6. Al Suwaidi J., Reddan D.N., Williams K., Pieper K.S., Harrington R.A., Califf R.M., et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002, 106:974-980.
7. Freeman R.V., Mehta R.H., Al Badr W., Cooper J.V., Kline-Rogers E., Eagle K.A. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003, 41:718-724.
8. Anavekar N.S., McMurray J.J.V., Velazquez E.J., Solomon S.D., Kober L., Rouleau J.-L., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351:1285-1295.
9. Rifkin D.E., Sarnak M.J. Absence of evidence or evidence of absence? ACS treatment in CKD. Nat Rev Nephrol 2010, 6:449-450.
10. Astor B.C., Levey A.S., Stevens L.A., Van Lente F., Selvin E., Coresh J. Method of glomerular filtration rate estimation affects prediction of mortality risk. J Am Soc Nephrol 2009, 20:2214-2222.
11. Peralta C.A., Katz R., Sarnak M.J., Ix J., Fried L.F., De Boer I., et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011, 22:147-155.
12. Jernberg T., Lindahl B., James S., Larsson A., Hansson L.-O., Wallentin L. A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004, 110:2342-2348.
13. Koenig W., Twardella D., Brenner H., Rotherbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005, 51:321-327.
14. Keller T., Messow C.M., Lubos E., Nicaud V., Wild P.S., Rupprecht H.J., et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J 2009, 30:314-320.
15. Taglieri N., Fernandez-Berges D.J., Koenig W., Consuegra-Sanchez L., Fernandez J.-M., Robles N.R., et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis 2010, 209:300-305.
16. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352:2049-2060.
17. Shlipak M.G., Katz R., Sarnak M.J., Fried L.F., Newman A.B., Stehman-Breen C., et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006, 145:237-246.
18. Ristiniemi N., Qin Q.-P., Postnikov A., Grubb A., Pettersson K. Dry-reagent double-monoclonal assay for cystatin C. Clin Chem 2010, 56:1424-1431.
19. Ristiniemi N., Savage C., Bruun L., Pettersson K., Lilja H., Christensson A. Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function. Nephrol Dial Transplant 2012, 27:682-687.
20. Eriksson S., Ilva T., Becker C., Lund J., Porela P., Pulkki K., et al. Comparison of cardiac troponin I immunoassays variably affected by circulating autoantibodies. Clin Chem 2005, 51:848-855.
21. Ilva T., Lund J., Porela P., Mustonen H., Voipio-Pulkki L.-M., Eriksson S., et al. Early markers of myocardial injury: cTnI is enough. Clin Chim Acta 2009, 400:82-85.
22. Lövgren T., Meriö L., Mitrunen K., Mäkinen M.-L., Mäkelä M., Blomberg K., et al. One-step all-in-one dry reagent immunoassays with fluorescent europium chelate label and time-resolved fluorometry. Clin Chem 1996, 42:1196-1201.
23. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
24. duBois D., duBois E.F. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916, 17:863-871.
25. Kidney disease outcome quality initiative: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39:S76-S92.
26. Levey A.S., Eckardt K.U., Tsukamoto Y., Levin A., Coresh J., Rossert J., et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
27. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130:461-470.
28. Vergara I.A., Norambuena T., Ferrada E., Slater A.W., Melo F. StAR: a simple tool for the statistical comparison of ROC curves. BMC Bioinformatics 2008, 9:265.
29. Lindeman R.D., Tobin J., Shock N.W. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985, 33:278-285.
30. Tonelli M., sacks F., Pfeffer M., Jhangri G.S., Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005, 68:237-245.
31. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
32. Shlipak M.G., Wassel Fyr C.L., Chertow G.M., Harris T.B., Kritchevsky S.B., Tylavsky F.A., et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006, 17:254-261.
33. Shlipak M.G., Katz R., Kestenbaum B., Fried L.F., Newman A.B., Siscovick D.S., et al. Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am J Nephrol 2009, 30:171-178.
34. Christensson A., Elmståhl S. Estimation of the age-dependent decline of glomerular filtration rate from formulas based on creatinine and cystatin C in the general elderly population. Nephron Clin Pract 2011, 117:c40-c50.
35. Stevens L.A., Levey A.S. Chronic kidney disease in the elderly - how to assess risk. N Engl J Med 2005, 352:2122-2124.